Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339324 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
A Phase 1 study, sponsored by Yana Najjar.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02339324: Completed Phase 1 study, sponsored by Yana Najjar.
NCT02339324 is a Phase 1 study that has completed, run by Yana Najjar. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02339324, a Phase 1 study, has completed, sponsored by Yana Najjar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study plans to to estimate the safety profile of the combination biotherapy regimen consisting of standard-dose interferon alpha-2b (HDI) and anti-PD1 monoclonal antibody, Pembrolizumab, for the neoadjuvant therapy of locally/regionally advanced/recurrent melanoma. Also, the objectives of this trial include the evaluation of prognostic and predictive biomarkers, radiologic preoperative response rate, pathologic response rate, progression free survival and overall survival. Up to 30 evaluable patients will be accrued.
Interventions
- DRUG Pembrolizumab and high dose interferon alfa-2b (HDI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-03-06 |
| Est. Completion | 2019-11-02 |
| Phase | Phase 1 |
What the finished NCT02339324 record still lists
NCT02339324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab and high dose interferon alfa-2b (HDI) is the first listed.
NCT02339324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02339324 about?
NCT02339324 is a clinical study titled "Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b". This study plans to to estimate the safety profile of the combination biotherapy regimen consisting of standard-dose interferon alpha-2b (HDI) and anti-PD1 monoclonal antibody, Pembrolizumab, for the neoadjuvant therapy of locally/regionally advanced/recurrent melanoma. Also, the objectives of this ...
What is the current status of trial NCT02339324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2015-03-06. Estimated completion is 2019-11-02.
What interventions are being tested in trial NCT02339324?
The interventions under investigation include: Pembrolizumab and high dose interferon alfa-2b (HDI) (DRUG).
Who is sponsoring clinical trial NCT02339324?
This trial is sponsored by Yana Najjar, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02339324's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI